{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:56:37Z","timestamp":1793955397856,"version":"4.8.0"},"publisher-location":"Cham","reference-count":150,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319717784","type":"print"},{"value":"9783319717791","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-71779-1_1","type":"book-chapter","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T04:51:01Z","timestamp":1518151861000},"page":"1-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["Clinical Features of Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Rhia","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,10]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR (2014) Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord 29:105\u2013114","journal-title":"Mov Disord"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ (2011) Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83\u201398","journal-title":"Lancet Neurol"},{"key":"1_CR3","unstructured":"Harper P (2002) The epidemiology of Huntington\u2019s disease. Huntington\u2019s disease. Oxford Medical Publications, Oxford"},{"issue":"10","key":"1_CR4","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"Stephen JW Evans","year":"2013","unstructured":"Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L (2013) Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"1_CR5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(10)60974-9","volume":"376","author":"M Rawlins","year":"2010","unstructured":"Rawlins M (2010) Huntington\u2019s disease out of the closet? Lancet 376:1372\u20131373","journal-title":"Lancet"},{"issue":"13","key":"1_CR6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/mds.25266","volume":"27","author":"Patrick J. Morrison","year":"2012","unstructured":"Morrison PJ (2012) Prevalence estimates of Huntington disease in Caucasian populations are gross underestimates. Mov Disord 27:1707\u20131708. (author reply 8\u20139)","journal-title":"Movement Disorders"},{"key":"1_CR7","first-page":"131","volume-title":"Bates G","author":"C Kay","year":"2014","unstructured":"Kay C, Fisher E, Michael H (2014) Epidemiology. In: Tabrizi SJ, Jones L (eds) Bates G. Oxford University Press, Huntington\u2019s disease, pp 131\u2013164"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","volume":"306","author":"JF Gusella","year":"1983","unstructured":"Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington\u2019s disease. Nature 306:234\u2013238","journal-title":"Nature"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72:971\u2013983","journal-title":"Cell"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ng0893-393","volume":"4","author":"RG Snell","year":"1993","unstructured":"Snell RG, MacMillan JC, Cheadle JP et al (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington\u2019s disease. Nat Genet 4:393\u2013397","journal-title":"Nat Genet"},{"key":"1_CR11","first-page":"16","volume":"59","author":"DC Rubinsztein","year":"1996","unstructured":"Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59:16\u201322","journal-title":"Am J Hum Genet"},{"key":"1_CR12","doi-asserted-by":"crossref","unstructured":"Killoran A, Biglan KM, Jankovic J, et al (2013) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology","DOI":"10.1212\/WNL.0b013e318294b304"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/jmedgenet-2013-101796","volume":"50","author":"A Semaka","year":"2013","unstructured":"Semaka A, Kay C, Doty C et al (2013) CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. J Med Genet 50:696\u2013703","journal-title":"J Med Genet"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/hmg\/2.12.2063","volume":"2","author":"C Z\u00fchlke","year":"1993","unstructured":"Z\u00fchlke C, Riess O, Bockel B, Lange H, Thies U (1993) Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum Mol Genet 2:2063\u20132067","journal-title":"Hum Mol Genet"},{"key":"1_CR15","first-page":"343","volume":"57","author":"B Kremer","year":"1995","unstructured":"Kremer B, Almqvist E, Theilmann J et al (1995) Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet 57:343\u2013350","journal-title":"Am J Hum Genet"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(70)92119-7","volume":"2","author":"A Barbeau","year":"1970","unstructured":"Barbeau A (1970) Parental ascent in the juvenile form of Huntington\u2019s chorea. Lancet 2:937","journal-title":"Lancet"},{"key":"1_CR17","unstructured":"Kremer B (2002) Clinical Neurology of Huntington\u2019s disease. In: Harper P, (ed) Huntington\u2019s disease. Oxford Medical Publications, Oxford"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/jnnp.69.1.54","volume":"69","author":"S Siesling","year":"2000","unstructured":"Siesling S, Vegter-van de Vlis M, Losekoot M et al (2000) Family history and DNA analysis in patients with suspected Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 69:54\u201359","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","volume":"29","author":"JF Gusella","year":"2014","unstructured":"Gusella JF, MacDonald ME, Lee JM (2014) Genetic modifiers of Huntington\u2019s disease. Mov Disord 29:1359\u20131365","journal-title":"Mov Disord"},{"key":"1_CR20","doi-asserted-by":"crossref","unstructured":"Consortium GMoHsDG-H (2015) Identification of Genetic Factors that Modify Clinical Onset of Huntington\u2019s Disease. Cell 162:516\u201326","DOI":"10.1016\/j.cell.2015.07.003"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler NS, Lorimer J, Porter J et al (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci U S A 101:3498\u20133503","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR (2004) Group IHsDC. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet 65:267\u2013277","journal-title":"Clin Genet"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","volume":"82","author":"EH Aylward","year":"2011","unstructured":"Aylward EH, Nopoulos PC, Ross CA et al (2011) Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82:405\u2013410","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mds.24024","volume":"27","author":"A Rosenblatt","year":"2012","unstructured":"Rosenblatt A, Kumar BV, Mo A, Welsh CS, Margolis RL, Ross CA (2012) Age, CAG repeat length, and clinical progression in Huntington\u2019s disease. Mov Disord 27:272\u2013276","journal-title":"Mov Disord"},{"key":"1_CR25","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ, Scahill RI, Owen G, et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90:905\u2013981","journal-title":"Physiol Rev"},{"key":"1_CR27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1006\/exnr.1998.6919","volume":"154","author":"GM Halliday","year":"1998","unstructured":"Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E (1998) Regional specificity of brain atrophy in Huntington\u2019s disease. Exp Neurol 154:663\u2013672","journal-title":"Exp Neurol"},{"key":"1_CR28","doi-asserted-by":"crossref","unstructured":"Hughes A, Jones L (2014) Pathogenic mechanisms in Huntington\u2019s disease. In: Bates GP, Tabrizi SJ, Jones L (eds) Huntington\u2019s Disease, 4th edn. Oxford University Press","DOI":"10.1093\/med\/9780199929146.003.0013"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA et al (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A 110:2366\u20132370","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506","journal-title":"Cell"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/hmg\/ddu504","volume":"24","author":"BA Barbaro","year":"2015","unstructured":"Barbaro BA, Lukacsovich T, Agrawal N et al (2015) Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington\u2019s disease. Hum Mol Genet 24:913\u2013925","journal-title":"Hum Mol Genet"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"14992","DOI":"10.1038\/srep14992","volume":"5","author":"CS Sun","year":"2015","unstructured":"Sun CS, Lee CC, Li YN et al (2015) Conformational switch of polyglutamine-expanded huntingtin into benign aggregates leads to neuroprotective effect. Sci Rep 5:14992","journal-title":"Sci Rep"},{"key":"1_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","volume":"238","author":"M Arrasate","year":"2012","unstructured":"Arrasate M, Finkbeiner S (2012) Protein aggregates in Huntington\u2019s disease. Exp Neurol 238:1\u201311","journal-title":"Exp Neurol"},{"key":"1_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","volume":"18","author":"C Zuccato","year":"2008","unstructured":"Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington\u2019s disease. Brain Pathol 18:225\u2013238","journal-title":"Brain Pathol"},{"key":"1_CR35","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","volume":"97","author":"JS Steffan","year":"2000","unstructured":"Steffan JS, Kazantsev A, Spasic-Boskovic O et al (2000) The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97:6763\u20136768","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","volume":"35","author":"C Zuccato","year":"2003","unstructured":"Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 35:76\u201383","journal-title":"Nat Genet"},{"key":"1_CR37","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/hmg\/ddl013","volume":"15","author":"A Hodges","year":"2006","unstructured":"Hodges A, Strand AD, Aragaki AK et al (2006) Regional and cellular gene expression changes in human Huntington\u2019s disease brain. Hum Mol Genet 15:965\u2013977","journal-title":"Hum Mol Genet"},{"key":"1_CR38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrn1989","volume":"7","author":"R Butler","year":"2006","unstructured":"Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7:784\u2013796","journal-title":"Nat Rev Neurosci"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","volume":"66","author":"N Pavese","year":"2006","unstructured":"Pavese N, Gerhard A, Tai YF et al (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638\u20131643","journal-title":"Neurology"},{"key":"1_CR40","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A et al (2007) Microglial activation in presymptomatic Huntington\u2019s disease gene carriers. Brain 130:1759\u20131766","journal-title":"Brain"},{"key":"1_CR41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","volume":"17","author":"A Crotti","year":"2014","unstructured":"Crotti A, Benner C, Kerman BE et al (2014) Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci 17:513\u2013521","journal-title":"Nat Neurosci"},{"key":"1_CR42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bj\u00f6rkqvist","year":"2008","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J Exp Med 205:1869\u20131877","journal-title":"J Exp Med"},{"key":"1_CR43","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nn.3761","volume":"17","author":"E Pecho-Vrieseling","year":"2014","unstructured":"Pecho-Vrieseling E, Rieker C, Fuchs S et al (2014) Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat Neurosci 17:1064\u20131072","journal-title":"Nat Neurosci"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","volume":"76","author":"F Cicchetti","year":"2014","unstructured":"Cicchetti F, Lacroix S, Cisbani G et al (2014) Mutant huntingtin is present in neuronal grafts in huntington disease patients. Ann Neurol 76:31\u201342","journal-title":"Ann Neurol"},{"key":"1_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-3-17","volume":"3","author":"R Pardo","year":"2010","unstructured":"Pardo R, Molina-Calavita M, Poizat G, Keryer G, Humbert S, Saudou F (2010) pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain 3:17","journal-title":"Mol Brain"},{"key":"1_CR46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","volume":"118","author":"LR Gauthier","year":"2004","unstructured":"Gauthier LR, Charrin BC, Borrell-Pag\u00e8s M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127\u2013138","journal-title":"Cell"},{"key":"1_CR47","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.nbd.2011.11.002","volume":"45","author":"JC Roux","year":"2012","unstructured":"Roux JC, Zala D, Panayotis N, Borges-Correia A, Saudou F, Villard L (2012) Modification of Mecp2 dosage alters axonal transport through the Huntingtin\/Hap1 pathway. Neurobiol Dis 45:786\u2013795","journal-title":"Neurobiol Dis"},{"key":"1_CR48","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/hmg\/ddg218","volume":"12","author":"H Li","year":"2003","unstructured":"Li H, Wyman T, Yu ZX, Li SH, Li XJ (2003) Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 12:2021\u20132030","journal-title":"Hum Mol Genet"},{"key":"1_CR49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10863-010-9286-7","volume":"42","author":"YN Jin","year":"2010","unstructured":"Jin YN, Johnson GV (2010) The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr 42:199\u2013205","journal-title":"J Bioenerg Biomembr"},{"key":"1_CR50","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.freeradbiomed.2012.06.008","volume":"53","author":"A Siddiqui","year":"2012","unstructured":"Siddiqui A, Rivera-S\u00e1nchez S, MeR Castro et al (2012) Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington\u2019s disease. Free Radic Biol Med 53:1478\u20131488","journal-title":"Free Radic Biol Med"},{"key":"1_CR51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/321168a0","volume":"321","author":"MF Beal","year":"1986","unstructured":"Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington\u2019s disease by quinolinic acid. Nature 321:168\u2013171","journal-title":"Nature"},{"key":"1_CR52","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1523\/JNEUROSCI.5687-08.2009","volume":"29","author":"PR Joshi","year":"2009","unstructured":"Joshi PR, Wu NP, Andr\u00e9 VM et al (2009) Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29:2414\u20132427","journal-title":"J Neurosci"},{"key":"1_CR53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.neuroscience.2007.03.010","volume":"147","author":"CL Benn","year":"2007","unstructured":"Benn CL, Slow EJ, Farrell LA et al (2007) Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington\u2019s disease. Neuroscience 147:354\u2013372","journal-title":"Neuroscience"},{"key":"1_CR54","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10571-010-9543-7","volume":"30","author":"SS Huang","year":"2010","unstructured":"Huang SS, He J, Zhao DM, Xu XY, Tan HP, Li H (2010) Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions. Cell Mol Neurobiol 30:1107\u20131115","journal-title":"Cell Mol Neurobiol"},{"key":"1_CR55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nn.3691","volume":"17","author":"X Tong","year":"2014","unstructured":"Tong X, Ao Y, Faas GC et al (2014) Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington\u2019s disease model mice. Nat Neurosci 17:694\u2013703","journal-title":"Nat Neurosci"},{"key":"1_CR56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nature06022","volume":"448","author":"EJ Bennett","year":"2007","unstructured":"Bennett EJ, Shaler TA, Woodman B et al (2007) Global changes to the ubiquitin system in Huntington\u2019s disease. Nature 448:704\u2013708","journal-title":"Nature"},{"key":"1_CR57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nn.2528","volume":"13","author":"M Martinez-Vicente","year":"2010","unstructured":"Martinez-Vicente M, Talloczy Z, Wong E et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington\u2019s disease. Nat Neurosci 13:567\u2013576","journal-title":"Nat Neurosci"},{"key":"1_CR58","doi-asserted-by":"crossref","first-page":"e46834","DOI":"10.1371\/journal.pone.0046834","volume":"7","author":"L Qi","year":"2012","unstructured":"Qi L, Zhang XD, Wu JC et al (2012) The role of chaperone-mediated autophagy in huntingtin degradation. PLoS ONE 7:e46834","journal-title":"PLoS ONE"},{"key":"1_CR59","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","volume":"12","author":"L Kennedy","year":"2003","unstructured":"Kennedy L, Evans E, Chen CM et al (2003) Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12:3359\u20133367","journal-title":"Hum Mol Genet"},{"key":"1_CR60","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","volume":"18","author":"M Swami","year":"2009","unstructured":"Swami M, Hendricks AE, Gillis T et al (2009) Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet 18:3039\u20133047","journal-title":"Hum Mol Genet"},{"key":"1_CR61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2008.09.014","volume":"33","author":"E Dragileva","year":"2009","unstructured":"Dragileva E, Hendricks A, Teed A et al (2009) Intergenerational and striatal CAG repeat instability in Huntington\u2019s disease knock-in mice involve different DNA repair genes. Neurobiol Dis 33:37\u201347","journal-title":"Neurobiol Dis"},{"key":"1_CR62","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 1:15005","journal-title":"Nat Rev Dis Primers"},{"key":"1_CR63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24\u00a0month observational data. Lancet Neurol 11:42\u201353","journal-title":"Lancet Neurol"},{"key":"1_CR64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204\u2013216","journal-title":"Nat Rev Neurol"},{"key":"1_CR65","first-page":"136","volume":"11","author":"K Kieburtz","year":"2001","unstructured":"Kieburtz K, Penney JB, Corno P, Ranen N, Shoulson I, Feigin A, Abwender D et al (2001) Unified Huntington\u2019s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 11:136\u2013142","journal-title":"Mov Disord"},{"key":"1_CR66","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874\u2013880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1_CR67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"E Duijn van","year":"2007","unstructured":"van Duijn E, Kingma EM, van der Mast RC (2007) Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441\u2013448","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1_CR68","unstructured":"Craufurd D, Snowden J (2002) Neuropsychological and neuropsychiatric aspects of Huntington\u2019s disease, in Huntington\u2019s disease. In: PS H (ed) Huntington\u2019s disease. Oxford Medical Publications, Oxford"},{"key":"1_CR69","doi-asserted-by":"crossref","first-page":"c3109","DOI":"10.1136\/bmj.c3109","volume":"340","author":"MJ Novak","year":"2010","unstructured":"Novak MJ, Tabrizi SJ (2010) Huntington\u2019s disease. BMJ 340:c3109","journal-title":"BMJ"},{"key":"1_CR70","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1988.00520320068017","volume":"45","author":"DJ Lanska","year":"1988","unstructured":"Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS (1988) Conditions associated with Huntington\u2019s disease at death. A case-control study. Arch Neurol 45:878\u2013880","journal-title":"Arch Neurol"},{"key":"1_CR71","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1176\/appi.ajp.162.4.725","volume":"162","author":"JS Paulsen","year":"2005","unstructured":"Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington\u2019s disease. Am J Psychiatry 162:725\u2013731","journal-title":"Am J Psychiatry"},{"key":"1_CR72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajmg.1320480412","volume":"48","author":"H Lipe","year":"1993","unstructured":"Lipe H, Schultz A, Bird TD (1993) Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am J Med Genet 48:231\u2013233","journal-title":"Am J Med Genet"},{"key":"1_CR73","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.parkreldis.2008.10.002","volume":"15","author":"A Videnovic","year":"2009","unstructured":"Videnovic A, Leurgans S, Fan W, Jaglin J, Shannon KM (2009) Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism. Relat Disord 15:471\u2013474","journal-title":"Relat Disord"},{"key":"1_CR74","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM Burg van der","year":"2009","unstructured":"van der Burg JM, Bj\u00f6rkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol 8:765\u2013774","journal-title":"Lancet Neurol"},{"key":"1_CR75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archneur.1991.00530200036015","volume":"48","author":"RH Myers","year":"1991","unstructured":"Myers RH, Sax DS, Koroshetz WJ et al (1991) Factors associated with slow progression in Huntington\u2019s disease. Arch Neurol 48:800\u2013804","journal-title":"Arch Neurol"},{"key":"1_CR76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","volume":"4","author":"SE Andrew","year":"1993","unstructured":"Andrew SE, Goldberg YP, Kremer B et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease. Nat Genet 4:398\u2013403","journal-title":"Nat Genet"},{"key":"1_CR77","doi-asserted-by":"crossref","unstructured":"Craufurd D, MacLeod R, Frontali M, et al (2014) Diagnostic genetic testing for Huntington\u2019s disease. Pract Neurol","DOI":"10.1136\/practneurol-2013-000790"},{"key":"1_CR78","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/mds.21915","volume":"23","author":"EJ Wild","year":"2008","unstructured":"Wild EJ, Mudanohwo EE, Sweeney MG et al (2008) Huntington\u2019s disease phenocopies are clinically and genetically heterogeneous. Mov Disord 23:716\u2013720","journal-title":"Mov Disord"},{"key":"1_CR79","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.0000000000000061","volume":"82","author":"DJ Hensman Moss","year":"2014","unstructured":"Hensman Moss DJ, Poulter M, Beck J et al (2014) C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82:292\u2013299","journal-title":"Neurology"},{"key":"1_CR80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","volume":"98","author":"MJ Novak","year":"2011","unstructured":"Novak MJ, Tabrizi SJ (2011) Huntington\u2019s disease: clinical presentation and treatment. Int Rev Neurobiol 98:297\u2013323","journal-title":"Int Rev Neurobiol"},{"key":"1_CR81","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","volume":"8","author":"RM Bonelli","year":"2007","unstructured":"Bonelli RM, Hofmann P (2007) A systematic review of the treatment studies in Huntington\u2019s disease since 1990. Expert Opin Pharmacother 8:141\u2013153","journal-title":"Expert Opin Pharmacother"},{"key":"1_CR82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"S Frank","year":"2014","unstructured":"Frank S (2014) Treatment of Huntington\u2019s disease. Neurotherapeutics 11:153\u2013160","journal-title":"Neurotherapeutics"},{"key":"1_CR83","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Group HS","year":"2006","unstructured":"Group HS (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366\u2013372","journal-title":"Neurology"},{"key":"1_CR84","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","volume":"8","author":"DR Guay","year":"2010","unstructured":"Guay DR (2010) Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 8:331\u2013373","journal-title":"Am J Geriatr Pharmacother"},{"key":"1_CR85","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev CD006456","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"1_CR86","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jmg.29.12.915","volume":"29","author":"D Craufurd","year":"1992","unstructured":"Craufurd D, Tyler A (1992) Predictive testing for Huntington\u2019s disease: protocol of the UK Huntington\u2019s Prediction Consortium. J Med Genet 29:915\u2013918","journal-title":"J Med Genet"},{"key":"1_CR87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jmg.27.1.34","volume":"27","author":"L Went","year":"1990","unstructured":"Went L (1990) Ethical issues policy statement on Huntington\u2019s disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology. J Med Genet 27:34\u201338","journal-title":"J Med Genet"},{"key":"1_CR88","unstructured":"Guidelines for the molecular genetics predictive test in Huntington\u2019s disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington\u2019s Chorea. Neurology 1994;44:1533\u20136"},{"key":"1_CR89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cge.12324","volume":"85","author":"A Semaka","year":"2014","unstructured":"Semaka A, Hayden MR (2014) Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results. Clin Genet 85:303\u2013311","journal-title":"Clin Genet"},{"key":"1_CR90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/jmg.37.8.567","volume":"37","author":"PS Harper","year":"2000","unstructured":"Harper PS, Lim C, Craufurd D (2000) Ten years of presymptomatic testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s Disease Prediction Consortium. J Med Genet 37:567\u2013571","journal-title":"J Med Genet"},{"key":"1_CR91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/hmg\/ddv442","volume":"25","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Kordasiewicz HB, McBride JL (2016) Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia. Hum Mol Genet 25:53\u201364","journal-title":"Hum Mol Genet"},{"key":"1_CR92","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X et al (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102:5820\u20135825","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR93","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","volume":"25","author":"LM Stanek","year":"2014","unstructured":"Stanek LM, Sardi SP, Mastis B et al (2014) Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease. Hum Gene Ther 25:461\u2013474","journal-title":"Hum Gene Ther"},{"key":"1_CR94","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74:1031\u20131044","journal-title":"Neuron"},{"key":"1_CR95","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau RL et al (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol Ther 19:2152\u20132162","journal-title":"Mol Ther"},{"key":"1_CR96","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y et al (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135:1197\u20131209","journal-title":"Brain"},{"key":"1_CR97","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","volume":"12","author":"NA Datson","year":"2017","unstructured":"Datson NA, Gonz\u00e1lez-Barriga A, Kourkouta E et al (2017) The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE 12:e0171127","journal-title":"PLoS ONE"},{"key":"1_CR98","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J et al (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19:774\u2013778","journal-title":"Curr Biol"},{"key":"1_CR99","doi-asserted-by":"crossref","first-page":"46740","DOI":"10.1038\/srep46740","volume":"7","author":"JRC Miller","year":"2017","unstructured":"Miller JRC, Pfister EL, Liu W et al (2017) Allele-selective suppression of mutant Huntingtin in primary human blood cells. Sci Rep 7:46740","journal-title":"Sci Rep"},{"key":"1_CR100","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","volume":"22","author":"AL Southwell","year":"2014","unstructured":"Southwell AL, Skotte NH, Kordasiewicz HB et al (2014) In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther 22:2093\u20132106","journal-title":"Mol Ther"},{"key":"1_CR101","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Warby SC, Southwell AL et al (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther 19:2178\u20132185","journal-title":"Mol Ther"},{"key":"1_CR102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox DB, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21:121\u2013131","journal-title":"Nat Med"},{"key":"1_CR103","first-page":"4566","volume":"25","author":"JW Shin","year":"2016","unstructured":"Shin JW, Kim KH, Chao MJ et al (2016) Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet 25:4566\u20134576","journal-title":"Hum Mol Genet"},{"key":"1_CR104","unstructured":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington\u2019s Disease. NCT02519036. Aug 1st 2015"},{"key":"1_CR105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W et al (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12:435\u2013442","journal-title":"Lancet Neurol"},{"key":"1_CR106","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017\u20133026","journal-title":"Lancet"},{"key":"1_CR107","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"A Pardo Di","year":"2012","unstructured":"Di Pardo A, Maglione V, Alpaugh M et al (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109:3528\u20133533","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"SD S\u00fcssmuth","year":"2015","unstructured":"S\u00fcssmuth SD, Haider S, Landwehrmeyer GB et al (2015) An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol 79:465\u2013476","journal-title":"Br J Clin Pharmacol"},{"key":"1_CR109","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1371\/journal.pone.0013417","volume":"5","author":"C Giamp\u00e0","year":"2010","unstructured":"Giamp\u00e0 C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE 5:e13417","journal-title":"PLoS ONE"},{"key":"1_CR110","unstructured":"Health NIo. A Phase 2, Double-Blind Randomized, Sequential Treatment Group, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-Striatal Function Of 2 Doses Of PF-02545920 In Subjects With Early Huntington\u2019s Disease. Pfizer; 2014"},{"key":"1_CR111","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1523\/JNEUROSCI.1310-13.2013","volume":"33","author":"DA Simmons","year":"2013","unstructured":"Simmons DA, Belichenko NP, Yang T et al (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6\/2 and BACHD mouse models of Huntington\u2019s disease. J Neurosci 33:18712\u201318727","journal-title":"J Neurosci"},{"key":"1_CR112","doi-asserted-by":"crossref","first-page":"e87923","DOI":"10.1371\/journal.pone.0087923","volume":"9","author":"D Todd","year":"2014","unstructured":"Todd D, Gowers I, Dowler SJ et al (2014) A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington\u2019s disease. PLoS ONE 9:e87923","journal-title":"PLoS ONE"},{"key":"1_CR113","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.27010","volume":"32","author":"C Verny","year":"2017","unstructured":"Verny C, Bachoud-L\u00e9vi AC, Durr A et al (2017) A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington\u2019s disease. Mov Disord 32:932\u2013936","journal-title":"Mov Disord"},{"key":"1_CR114","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling D, Huang SY, Sathyasaikumar KV et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863\u2013874","journal-title":"Cell"},{"key":"1_CR115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2016.05.005","volume":"282","author":"V Beaumont","year":"2016","unstructured":"Beaumont V, Mrzljak L, Dijkman U et al (2016) The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington\u2019s disease. Exp Neurol 282:99\u2013118","journal-title":"Exp Neurol"},{"key":"1_CR116","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","volume":"124","author":"W Br\u00fcck","year":"2012","unstructured":"Br\u00fcck W, Pf\u00f6rtner R, Pham T et al (2012) Reduced astrocytic NF-\u03baB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 124:411\u2013424","journal-title":"Acta Neuropathol"},{"key":"1_CR117","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L et al (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366:1000\u20131009","journal-title":"N Engl J Med"},{"key":"1_CR118","unstructured":"A Clinical Study in Subjects With Huntington\u2019s Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod (LEGATO-HD). Teva Branded Pharmaceutical Products, R&D Inc. 2016 ongoing"},{"key":"1_CR119","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jnc.12190","volume":"125","author":"J Jin","year":"2013","unstructured":"Jin J, Albertz J, Guo Z et al (2013) Neuroprotective effects of PPAR-\u03b3 agonist rosiglitazone in N171-82Q mouse model of Huntington\u2019s disease. J Neurochem 125:410\u2013419","journal-title":"J Neurochem"},{"key":"1_CR120","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: What\u2019s in the pipeline? Mov Disord 29:1434\u20131445","journal-title":"Mov Disord"},{"key":"1_CR121","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.neuroscience.2008.02.004","volume":"153","author":"BR Miller","year":"2008","unstructured":"Miller BR, Dorner JL, Shou M et al (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington\u2019s disease phenotype in the R6\/2 mouse. Neuroscience 153:329\u2013337","journal-title":"Neuroscience"},{"key":"1_CR122","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1073\/pnas.1222663110","volume":"110","author":"EM Sontag","year":"2013","unstructured":"Sontag EM, Joachimiak LA, Tan Z et al (2013) Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc Natl Acad Sci U S A 110:3077\u20133082","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR123","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/brain\/aws022","volume":"135","author":"J Labbadia","year":"2012","unstructured":"Labbadia J, Novoselov SS, Bett JS et al (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 135:1180\u20131196","journal-title":"Brain"},{"key":"1_CR124","doi-asserted-by":"crossref","first-page":"e1001717","DOI":"10.1371\/journal.pbio.1001717","volume":"11","author":"M Mielcarek","year":"2013","unstructured":"Mielcarek M, Landles C, Weiss A et al (2013) HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 11:e1001717","journal-title":"PLoS Biol"},{"key":"1_CR125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker RA, Mason SL, Harrower TP et al (2013) The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 84:657\u2013665","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1_CR126","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/jnnp.2007.142380","volume":"79","author":"I Reuter","year":"2008","unstructured":"Reuter I, Tai YF, Pavese N et al (2008) Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 79:948\u2013951","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1_CR127","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","volume":"356","author":"AC Bachoud-L\u00e9vi","year":"2000","unstructured":"Bachoud-L\u00e9vi AC, R\u00e9my P, Nguyen JP et al (2000) Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation. Lancet 356:1975\u20131979","journal-title":"Lancet"},{"key":"1_CR128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","volume":"5","author":"AC Bachoud-L\u00e9vi","year":"2006","unstructured":"Bachoud-L\u00e9vi AC, Gaura V, Brugi\u00e8res P et al (2006) Effect of fetal neural transplants in patients with Huntington\u2019s disease 6\u00a0years after surgery: a long-term follow-up study. Lancet Neurol 5:303\u2013309","journal-title":"Lancet Neurol"},{"key":"1_CR129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neuroscience.2009.02.035","volume":"160","author":"P Capetian","year":"2009","unstructured":"Capetian P, Knoth R, Maciaczyk J et al (2009) Histological findings on fetal striatal grafts in a Huntington\u2019s disease patient early after transplantation. Neuroscience 160:661\u2013675","journal-title":"Neuroscience"},{"key":"1_CR130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.expneurol.2009.12.005","volume":"222","author":"P Gallina","year":"2010","unstructured":"Gallina P, Paganini M, Lombardini L et al (2010) Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington\u2019s disease patients after transplantation. Exp Neurol 222:30\u201341","journal-title":"Exp Neurol"},{"key":"1_CR131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","volume":"58","author":"RA Hauser","year":"2002","unstructured":"Hauser RA, Furtado S, Cimino CR et al (2002) Bilateral human fetal striatal transplantation in Huntington\u2019s disease. Neurology 58:687\u2013695","journal-title":"Neurology"},{"key":"1_CR132","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnint.2011.00078","volume":"5","author":"R Wijeyekoon","year":"2011","unstructured":"Wijeyekoon R, Barker RA (2011) The current status of neural grafting in the treatment of Huntington\u2019s disease. A Review. Front Integr Neurosci 5:78","journal-title":"Front Integr Neurosci"},{"key":"1_CR133","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev CD006455","DOI":"10.1002\/14651858.CD006455.pub2"},{"key":"1_CR134","unstructured":"Announcement of 2CARE Early Study Closure. http:\/\/huntingtonstudygroup.org\/tag\/2care\/2014"},{"key":"1_CR135","unstructured":"Group HS nnouncement of CREST-E Early Study Closure. http:\/\/huntingtonstudygroup.org\/tag\/crest-e\/2014"},{"key":"1_CR136","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"HSGH Investigators","year":"2013","unstructured":"Investigators HSGH (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord 28:1407\u20131415","journal-title":"Mov Disord"},{"key":"1_CR137","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG Yebenes de","year":"2011","unstructured":"de Yebenes JG, Landwehrmeyer B, Squitieri F et al (2011) Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:1049\u20131057","journal-title":"Lancet Neurol"},{"key":"1_CR138","unstructured":"Reilmann R, AM, Landwehrmeyer G, Kieburtz K, Grachev I, Eyal E, Savola J, Borowsky B, Papapetropoulos S, Hayden M (2017) Efficacy, safety, and tolerability of pridopidine in Huntington disease (HD): results from the phase ii dose-ranging study, pride-HD. In: 21st international congress of parkinson\u2019s disease and movement disorders, 2017, Vancouver, BC, Mov Disord. 32(suppl 2), http:\/\/www.mdsabstracts.org\/abstract\/efficacy-safety-and-tolerability-of-pridopidine-in-huntington-disease-hd-results-from-the-phase-ii-dose-ranging-study-pride-hd\/"},{"key":"1_CR139","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.0970","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D et al (2016) Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA 316:40\u201350","journal-title":"JAMA"},{"key":"1_CR140","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E et al (2017) Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol 74:977\u2013982","journal-title":"JAMA Neurol"},{"key":"1_CR141","unstructured":"Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington\u2019s Disease (HD) (HD-DBS). 2015, ongoing"},{"key":"1_CR142","doi-asserted-by":"crossref","unstructured":"Investigators HSGRH. Safety, tolerability, and efficacy of PBT2 in Huntington\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015;14:39\u201347","DOI":"10.1016\/S1474-4422(14)70262-5"},{"key":"1_CR143","unstructured":"Effects of EGCG (Epigallocatechin Gallate) in Huntington\u2019s Disease (ETON-Study) (ETON)"},{"key":"1_CR144","unstructured":"Neuroleptic and Huntington Disease Comparison of: Olanzapine, la Tetrabenazine and Tiapride (NEUROHD"},{"key":"1_CR145","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","volume":"123","author":"CC Tang","year":"2013","unstructured":"Tang CC, Feigin A, Ma Y et al (2013) Metabolic network as a progression biomarker of premanifest Huntington\u2019s disease. J Clin Invest 123:4076\u20134088","journal-title":"J Clin Invest"},{"key":"1_CR146","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.0b013e3181fc27e4","volume":"75","author":"A Sturrock","year":"2010","unstructured":"Sturrock A, Laule C, Decolongon J et al (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75:1702\u20131710","journal-title":"Neurology"},{"key":"1_CR147","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/mds.25964","volume":"29","author":"JC Stout","year":"2014","unstructured":"Stout JC, Queller S, Baker KN et al (2014) HD-CAB: a cognitive assessment battery for clinical trials in Huntington\u2019s disease 1,2,3. Mov Disord 29:1281\u20131288","journal-title":"Mov Disord"},{"key":"1_CR148","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest 125:1979\u20131986","journal-title":"J Clin Invest"},{"key":"1_CR149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jnc.13719","volume":"139","author":"FB Rodrigues","year":"2016","unstructured":"Rodrigues FB, Byrne L, McColgan P et al (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington\u2019s disease. J Neurochem 139:22\u201325","journal-title":"J Neurochem"},{"key":"1_CR150","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis. Lancet Neurol 16:601\u2013609","journal-title":"Lancet Neurol"}],"container-title":["Advances in Experimental Medicine and Biology","Polyglutamine Disorders"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-71779-1_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T13:50:22Z","timestamp":1570715422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-71779-1_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319717784","9783319717791"],"references-count":150,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-71779-1_1","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}